MTI-GlobalStem has an active research program that utilizes expertise in transfection, neuroscience and stem cell biology to develop and supply scientists with the necessary tools and reagents to help advance new discoveries and developments in the life sciences. Utilizing our intellectual property and know-how, and a specialized team of highly skilled and experienced scientists, we are filling the gap with primary and iPSC-derived neural cells, stem cells and supporting feeder cells, optimized growth media and supplements, and an innovative platform of novel targeted reagents used to deliver nucleic acids into stem cells and neuronal cells with maximum efficiency.

Science & Technology Corp. provides scientific, technical, and engineering services. The firm Specializes in defense chemical and biological research, test and evaluation, range support services, earth and space sciences, polar technologies, aerospace engineering and information systems engineering and support. The company was founded in 1979 and is headquartered in Hampton, VA.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Wuhan YZY Biopharma Co., Ltd. engages in the research, development, and industrialization of bispecific drugs. The firm specializes in tumor immunotherapy and immune cell therapy. Its business scope includes research and development of biotechnology, technology transfer, and technical advisory services; and wholesale and retail of biological drugs. The company was founded by Peng Fei Zhou, Qian Yuan, and Hong Feng Zhou on July 8, 2010 and is headquartered in Wuhan, China.

ViiV Healthcare UK (No. 4) Ltd., a subsidiary of GSK Plc, is a company headquartered in Middlesex, UK, that engages in development, enhancement, maintenance, protection and exploitation of intellectual property assets. It was founded in 2015.

Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases. In recent years Kither has focused its first line of activities on the development of a small peptide (KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development. Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.

Regulon, Inc. is an American private company located in San Jose, CA. The firm engages in the discovery and development of nanopharmaceutics in oncology. It was founded in 1997. Teni Boulikas is currently the CEO of the company.

Biocompatibles UK Ltd. is a company headquartered in Farnham, UK, that manufactures, and markets implantable products for patients. The firm was founded in 2001.

CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.

Beijing Zeqin Biomedicine Co., Ltd., established on 2016-07-11, The scope of business includes retail pharmaceuticals;technology development,technology transfer,technical consulting,Technical Services;Sales of chemical products,food additives,Equipment.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

People affected by prostate cancer need breakthroughs. Research is the only way they can turn this hope to reality.

IDP Pharma is a drug discovery company that develops first-in-class medicines (New Chemical Entities) directed to a novel class of therapeutic targets, intrinsically disordered proteins (IDPs). They are currently focused on exploiting new mechanisms of action to treat cancer diseases. Multiple myeloma is one of their priorities. IDP Pharma's efforts are directed towards promoting a real shift in cancer therapies to improve the lives of patients. To this end, the company has built an extraordinary committed team of experts in the field, supported by a professional advisory board, including IDPs and diseases experts, and business professionals.

Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer. The company's Bone Marrow Engraftment Enhancer (BMEE) program is developing a first-line product, TBX-1400, to enhance the engraftment of hematopoietic stem and progenitor cells during an allogeneic hematopoietic stem cell transplant (HSCT). Taiga Biotechnologies lead Cell-Based Immunotherapy product candidate, TBX-3400, uses a patient’s own immune cells to help fight against cancer and infectious disease. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex vivo with our fusion protein and then delivered intravenously back to the patient the following day. They developing technologies to generate red blood cells in the laboratory for clinical applications and products to improve the utility of red blood cell products.

Ningbo Kunpeng Biotechnology Co., Ltd., established on 2016-04-18, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;Drug Wholesale;Drug import and export;Import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Anijen Co., Ltd. is the first bio-venture company in Gwangju and Jeonnam province. Since its establishment in 2000, it has developed peptide biomaterial process and developed quality management technology. They are making efforts to advance into the global market based on their competitiveness. In 2016, it was listed on the KOSDAQ market based on its proprietary peptide biomaterials and new drug development technology. They are supplying Peptide Medicinal Materials of high quality, which have been approved by GMP for the first time in Korea, at a reasonable price in the peptides drug materials market, which is dominated by a small number of companies worldwide. This stabilizes the supply price of peptide drug raw materials, And contribute to the promotion of public health.

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods. PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013. PhaseBio is based in Malvern, Pennsylvania.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

NIBEC Co., Ltd. engages in the development, manufacture, and commercialization of medical products and supplies. Its business areas include oral care products, bio materials for tissue regeneration, cosmetics and bio fusion peptide businesses. The Oral Care Products business offers tooth whitening, tooth desensitizer and dental conditioner. The Bio materials for Tissue Regeneration business offers bone graft materials, barrier, intra oral, resorbable collagen membrane matrix and growth-factor enhanced matrix. The Bio Fusion Peptide business provides bone graft material, biodegradable collagen matrix and synthetic bone graft material. The company was founded on February 20, 2004 and is headquartered in Jincheon-gun, South Korea.